Product Description
Mechanisms of Action: Immunomodulator, FGFR Inhibitor, HSP90 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | Canada | Egypt | Germany | India | Ireland | Portugal | Sweden
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/02/2023 |
News Article |
Flow Regulators Market, Business Summation, Industry Examination, Standpoint 2023 to 2029 |
|
09/29/2020 |
News Article |
Coated Abrasive Market Research Report Forecast (2020 -2026) |
|
10/21/2019 |
News Article |
Global Lichen Planus Pipeline Insights 2019 - ResearchAndMarkets.com |